Innocan Pharma Receives Third Consecutive FDA Fee Waiver for Cannabidiol-Based Pain Treatment in Dogs
Key Insights
The FDA's Center for Veterinary Medicine (search) granted Innocan Pharma a third consecutive annual fee waiver for its LPT-CBD product under the "significant barrier to innovation" provision.
The liposomal cannabidiol injection demonstrated statistically significant pain reduction in osteoarthritic dogs compared to placebo in a blinded crossover study.
The subcutaneous treatment is designed as a once-monthly administration for chronic pain management in dogs, targeting the growing U.S. pet market of 94 million households.
Innocan Pharma Corporation (search) has secured its third consecutive annual fee waiver from the FDA's Center for Veterinary Medicine (search) (CVM) for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product, highlighting continued regulatory recognition of the company's innovative approach to canine pain management. The waiver, granted under the "significant barrier to innovation" provision, supports the development of a subcutaneous cannabidiol injection for chronic pain in dogs.
Clinical Evidence Supports Therapeutic Potential
The LPT-CBD product candidate demonstrated promising efficacy in clinical testing. In a blinded, crossover study conducted on osteoarthritic dogs, the liposomal cannabidiol formulation showed statistically significant reduction in pain and meaningful improvements in overall well-being compared with placebo (empty liposomes). These results, combined with additional studies previously conducted in osteoarthritic dogs, provide robust evidence supporting LPT-CBD's analgesic potential as a treatment option for chronic pain management.
Addressing Market Need for Alternative Pain Solutions
"The veterinary market is open to new drug technologies that can address the limitations of current pain medications and offer a new alternative therapy," said Dr. Antonio Benitz, Innocan's animal health advisor. The treatment is designed to meet rising demand in the expanding U.S. pet market, which includes an estimated 94 million households owning at least one pet.
Dr. Eyal Kalo, Vice President of Research and Development at Innocan, emphasized the practical advantages of their approach: "Our technology is designed to meet rising demand for safe, effective chronic pain solutions, combining demonstrated therapeutic potential with the convenience of a single, once-monthly administration."
Regulatory Recognition of Innovation
The FDA's Center for Veterinary Medicine (search) assesses annual fees for animal drug applications, but sponsors developing innovative products may request fee waivers each year. Innocan submits annual renewal requests that include development progress updates and forward plans. The third consecutive waiver underscores CVM's continued recognition of Innocan's innovation-driven animal health program and reinforces the company's progress toward delivering new solutions for chronic pain in dogs.
The liposomal delivery platform represents a novel approach to cannabidiol administration, utilizing exact dosing and controlled release mechanisms for non-opioid pain management in veterinary applications.